Header Logo

Connection

Jinal Bhiman to HIV-1

This is a "connection" page, showing publications Jinal Bhiman has written about HIV-1.
Connection Strength

1,786
  1. Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses. Immunity. 2017 05 16; 46(5):762-764.
    View in: PubMed
    Score: 0,314
  2. Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep. 2017 04; 14(2):54-62.
    View in: PubMed
    Score: 0,311
  3. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,281
  4. SARS-CoV-2 humoral immunity in people living with HIV-1. Trends Immunol. 2024 Jul; 45(7):511-522.
    View in: PubMed
    Score: 0,128
  5. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
    View in: PubMed
    Score: 0,092
  6. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
    View in: PubMed
    Score: 0,086
  7. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,086
  8. Strategies for a multi-stage neutralizing antibody-based HIV vaccine. Curr Opin Immunol. 2018 08; 53:143-151.
    View in: PubMed
    Score: 0,084
  9. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
    View in: PubMed
    Score: 0,077
  10. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
    View in: PubMed
    Score: 0,071
  11. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
    View in: PubMed
    Score: 0,070
  12. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
    View in: PubMed
    Score: 0,061
  13. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
    View in: PubMed
    Score: 0,057
  14. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat Commun. 2021 08 10; 12(1):4817.
    View in: PubMed
    Score: 0,026
  15. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
    View in: PubMed
    Score: 0,024
  16. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
    View in: PubMed
    Score: 0,016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.